Hepatitis C Virus NS3/4A Protease Inhibitor
5 drugs across 3 manufacturers|0 Generic,5 Brand
The Hepatitis C Virus NS3/4A Protease Inhibitor class contains 5 NDCs from 3 manufacturers (0 generic, 5 brand), at an average NADAC of $390.42 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
5
0G / 5B
Manufacturers
3
Avg $390.4177/unit
Avg 7d Change
-0.01%
Across 3 drugs with changes
7d Activity
of 5 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Frequently Asked Questions
How many drugs are in the Hepatitis C Virus NS3/4A Protease Inhibitor class?
The Hepatitis C Virus NS3/4A Protease Inhibitor class contains 5 NDCs from 3 manufacturers — 0 generic and 5 brand products.
What is the average price of Hepatitis C Virus NS3/4A Protease Inhibitor drugs?
The average NADAC for the Hepatitis C Virus NS3/4A Protease Inhibitor class is $390.4177 per unit across 5 NDCs.
Which manufacturers make Hepatitis C Virus NS3/4A Protease Inhibitor drugs?
3 manufacturers make drugs in the Hepatitis C Virus NS3/4A Protease Inhibitor class. Ranked by number of NDCs, the largest are AbbVie Inc. (3), Gilead Sciences, Inc. (1), Merck Sharp & Dohme LLC (1).
How has Hepatitis C Virus NS3/4A Protease Inhibitor pricing changed recently?
Over the past 7 days, 0 NDCs in this class rose and 3 fell, with a class-wide average change of -0.0%.
Manufacturer Breakdown
3 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
VOSEVI 400-100-100 MG TABLET SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | $858.6884 per EA | — |
ZEPATIER 50-100 MG TABLET elbasvir and grazoprevir | $634.2375 per EA | — |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $153.0541 per EA | -0.01% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $153.0541 per EA | -0.01% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $153.0541 per EA | -0.01% |